116 related articles for article (PubMed ID: 30887054)
1. Does the Flemish colorectal cancer screening programme reach equity in FIT uptake?
Hoeck S; van de Veerdonk W; De Brabander I; Kellen E
Eur J Public Health; 2019 Dec; 29(6):1108-1114. PubMed ID: 30887054
[TBL] [Abstract][Full Text] [Related]
2. Do socioeconomic factors play a role in nonadherence to follow-up colonoscopy after a positive faecal immunochemical test in the Flemish colorectal cancer screening programme?
Hoeck S; van de Veerdonk W; De Brabander I
Eur J Cancer Prev; 2020 Mar; 29(2):119-126. PubMed ID: 31724969
[TBL] [Abstract][Full Text] [Related]
3. Population-based screening for colorectal cancer using an immunochemical faecal occult blood test: a comparison of two invitation strategies.
Van Roosbroeck S; Hoeck S; Van Hal G
Cancer Epidemiol; 2012 Oct; 36(5):e317-24. PubMed ID: 22560885
[TBL] [Abstract][Full Text] [Related]
4. Barriers and facilitators to participate in the colorectal cancer screening programme in Flanders (Belgium): a focus group study.
Hoeck S; Van Roy K; Willems S
Acta Clin Belg; 2022 Feb; 77(1):37-44. PubMed ID: 32552612
[TBL] [Abstract][Full Text] [Related]
5. Occurrence and characteristics of faecal immunochemical screen-detected cancers vs non-screen-detected cancers: Results from a Flemish colorectal cancer screening programme.
van de Veerdonk W; Hoeck S; Peeters M; Van Hal G; Francart J; De Brabander I
United European Gastroenterol J; 2020 Mar; 8(2):185-194. PubMed ID: 32213071
[TBL] [Abstract][Full Text] [Related]
6. Uptake of cancer screening among adults with disabilities in Flanders (Belgium).
Kellen E; Nuyens C; Molleman C; Hoeck S
J Med Screen; 2020 Mar; 27(1):48-51. PubMed ID: 31474187
[TBL] [Abstract][Full Text] [Related]
7. The Impact of a Six-Year Existing Screening Programme Using the Faecal Immunochemical Test in Flanders (Belgium) on Colorectal Cancer Incidence, Mortality and Survival: A Population-Based Study.
Tran TN; Hoeck S; De Schutter H; Janssens S; Peeters M; Van Hal G
Int J Environ Res Public Health; 2023 Jan; 20(2):. PubMed ID: 36674409
[TBL] [Abstract][Full Text] [Related]
8. Socio-demographic and cultural factors related to non-participation in the Dutch colorectal cancer screening programme.
van de Schootbrugge-Vandermeer HJ; Lansdorp-Vogelaar I; de Jonge L; van Vuuren AJ; Dekker E; Spaander MCW; Ramakers CRB; Nagtegaal ID; van Kemenade FJ; van Leerdam ME; Toes-Zoutendijk E
Eur J Cancer; 2023 Sep; 190():112942. PubMed ID: 37406529
[TBL] [Abstract][Full Text] [Related]
9. Decomposing socio-economic inequality in colorectal cancer screening uptake in England.
Solmi F; Von Wagner C; Kobayashi LC; Raine R; Wardle J; Morris S
Soc Sci Med; 2015 Jun; 134():76-86. PubMed ID: 25917138
[TBL] [Abstract][Full Text] [Related]
10. Screening for colorectal cancer: sense and sensibilities.
Van Hal G; Hoeck S; Van Roosbroeck S
Eur J Cancer; 2011 Sep; 47 Suppl 3():S156-63. PubMed ID: 21943969
[TBL] [Abstract][Full Text] [Related]
11. The role of area-level deprivation and gender in participation in population-based faecal immunochemical test (FIT) colorectal cancer screening.
Clarke N; McNamara D; Kearney PM; O'Morain CA; Shearer N; Sharp L
Prev Med; 2016 Dec; 93():198-203. PubMed ID: 27765660
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal Adherence to Immunochemical Fecal Occult Blood Testing vs Guaiac-based FOBT in an Organized Colorectal Cancer Screening Program.
Benito L; Travier N; Binefa G; Vidal C; Espinosa J; Milà N; Garcia M
Cancer Prev Res (Phila); 2019 May; 12(5):327-334. PubMed ID: 30890542
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England.
Murphy J; Halloran S; Gray A
BMJ Open; 2017 Oct; 7(10):e017186. PubMed ID: 29079605
[TBL] [Abstract][Full Text] [Related]
14. Uptake of a colorectal cancer screening blood test in people with elevated risk for cancer who cannot or will not complete a faecal occult blood test.
Symonds EL; Cock C; Meng R; Cole SR; Fraser RJL; Young GP
Eur J Cancer Prev; 2018 Sep; 27(5):425-432. PubMed ID: 28368949
[TBL] [Abstract][Full Text] [Related]
15. Inequalities in participation in an organized national colorectal cancer screening programme: results from the first 2.6 million invitations in England.
von Wagner C; Baio G; Raine R; Snowball J; Morris S; Atkin W; Obichere A; Handley G; Logan RF; Rainbow S; Smith S; Halloran S; Wardle J
Int J Epidemiol; 2011 Jun; 40(3):712-8. PubMed ID: 21330344
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of colorectal cancer screening across sociodemographic groups in Denmark: a register-based study.
Pallesen AVJ; Herrstedt J; Westendorp RGJ; Mortensen LH; Kristiansen M
Acta Oncol; 2021 Mar; 60(3):323-332. PubMed ID: 33427545
[TBL] [Abstract][Full Text] [Related]
17. Differences in diagnostic activity in general practice and findings for individuals invited to the danish screening programme for colorectal cancer: a population-based cohort study.
Juul JS; Andersen B; Laurberg S; Carlsen AH; Olesen F; Vedsted P
Scand J Prim Health Care; 2018 Sep; 36(3):281-290. PubMed ID: 29929415
[TBL] [Abstract][Full Text] [Related]
18. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
[TBL] [Abstract][Full Text] [Related]
19. Participation rates for organized colorectal cancer screening programmes: an international comparison.
Klabunde C; Blom J; Bulliard JL; Garcia M; Hagoel L; Mai V; Patnick J; Rozjabek H; Senore C; Törnberg S
J Med Screen; 2015 Sep; 22(3):119-26. PubMed ID: 25967088
[TBL] [Abstract][Full Text] [Related]
20. Risk stratification for colorectal neoplasia detection in the Flemish colorectal cancer screening programme.
van de Veerdonk W; Van Hal G; Peeters M; De Brabander I; Silversmit G; Hoeck S
Cancer Epidemiol; 2018 Oct; 56():90-96. PubMed ID: 30114631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
